Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

A gene expression phenotype in lymphocytes from Friedreich ataxia patients.

Coppola G, Burnett R, Perlman S, Versano R, Gao F, Plasterer H, Rai M, Saccá F, Filla A, Lynch DR, Rusche JR, Gottesfeld JM, Pandolfo M, Geschwind DH.

Ann Neurol. 2011 Nov;70(5):790-804. doi: 10.1002/ana.22526.

2.

Erythropoietin in Friedreich ataxia.

Mariotti C, Nachbauer W, Panzeri M, Poewe W, Taroni F, Boesch S.

J Neurochem. 2013 Aug;126 Suppl 1:80-7. doi: 10.1111/jnc.12301. Review.

3.

Neurodegeneration in Friedreich's ataxia: from defective frataxin to oxidative stress.

Gomes CM, Santos R.

Oxid Med Cell Longev. 2013;2013:487534. doi: 10.1155/2013/487534. Review.

4.

Targeting the gene in Friedreich ataxia.

Hebert MD.

Biochimie. 2008 Aug;90(8):1131-9. doi: 10.1016/j.biochi.2007.12.005. Review.

PMID:
18206656
5.

Iron metabolism and mitochondrial abnormalities in Friedreich ataxia.

Pandolfo M.

Blood Cells Mol Dis. 2002 Nov-Dec;29(3):536-47; discussion 548-52. Review.

PMID:
12547248
6.

Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxia.

Evans-Galea MV, Lockhart PJ, Galea CA, Hannan AJ, Delatycki MB.

Discov Med. 2014 Jan;17(91):25-35. Review.

7.

Friedreich's ataxia: past, present and future.

Marmolino D.

Brain Res Rev. 2011 Jun 24;67(1-2):311-30. doi: 10.1016/j.brainresrev.2011.04.001. Review.

PMID:
21550666
8.

Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia.

Vaubel RA, Isaya G.

Mol Cell Neurosci. 2013 Jul;55:50-61. doi: 10.1016/j.mcn.2012.08.003. Review.

9.

Friedreich Ataxia: From the Eye of a Molecular Biologist.

Muthuswamy S, Agarwal S.

Neurologist. 2015 Sep;20(3):51-5. doi: 10.1097/NRL.0000000000000054. Review.

PMID:
26375377
10.

Milestones in Friedreich ataxia: more than a century and still learning.

Abrahão A, Pedroso JL, Braga-Neto P, Bor-Seng-Shu E, de Carvalho Aguiar P, Barsottini OG.

Neurogenetics. 2015 Jul;16(3):151-60. doi: 10.1007/s10048-015-0439-z. Review.

PMID:
25662948
11.

Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.

Marmolino D, Acquaviva F.

Cerebellum. 2009 Sep;8(3):245-59. doi: 10.1007/s12311-008-0084-2. Review.

PMID:
19165552
12.

Animal and cellular models of Friedreich ataxia.

Perdomini M, Hick A, Puccio H, Pook MA.

J Neurochem. 2013 Aug;126 Suppl 1:65-79. doi: 10.1111/jnc.12219. Review.

13.

Therapeutic developments in Friedreich ataxia.

Wilson RB.

J Child Neurol. 2012 Sep;27(9):1212-6. doi: 10.1177/0883073812449691. Review.

14.

Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.

Santos R, Lefevre S, Sliwa D, Seguin A, Camadro JM, Lesuisse E.

Antioxid Redox Signal. 2010 Sep 1;13(5):651-90. doi: 10.1089/ars.2009.3015. Review.

15.

Multicellular models of Friedreich ataxia.

Puccio H.

J Neurol. 2009 Mar;256 Suppl 1:18-24. doi: 10.1007/s00415-009-1004-1. Review.

PMID:
19283346
16.

Gene-based approaches toward Friedreich ataxia therapeutics.

Hebert MD, Whittom AA.

Cell Mol Life Sci. 2007 Dec;64(23):3034-43. Review.

PMID:
17828464
17.

Mitochondrial dysfunction in friedreich's ataxia.

Lodi R, Taylor DJ, Schapira AH.

Biol Signals Recept. 2001 May-Aug;10(3-4):263-70. Review.

PMID:
11351132
18.

Friedreich ataxia: a paradigm for mitochondrial diseases.

Puccio H, Koenig M.

Curr Opin Genet Dev. 2002 Jun;12(3):272-7. Review.

PMID:
12076669

Supplemental Content

Support Center